Income Statement Dr. Lal PathLabs Limited
Stocks
LALPATHLAB
INE600L01024
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,692.80 INR | +0.49% |
|
+2.86% | +14.18% |
| 06-17 | Dr. Lal PathLabs' Volume Boom Comes at a Cost | |
| 05-04 | Nomura Adjusts Dr. Lal PathLabs' Price Target to INR1,860 From INR1,800, Keeps at Buy | MT |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 20.87B | 20.17B | 22.27B | 24.61B | 27.63B | |||||
Total Revenues | 20.87B | 20.17B | 22.27B | 24.61B | 27.63B | |||||
Cost of Goods Sold, Total | 9.2B | 8.92B | 9.48B | 10.37B | 11.19B | |||||
Gross Profit | 11.68B | 11.25B | 12.79B | 14.24B | 16.44B | |||||
Selling General & Admin Expenses, Total | 3.47B | 3.58B | 4.14B | 4.5B | 5.26B | |||||
Provision for Bad Debts | 6.16M | 36.47M | - | 11.25M | 8.79M | |||||
Depreciation & Amortization - (IS) | 1.08B | 1.5B | 1.44B | 1.42B | 1.62B | |||||
Other Operating Expenses | 2.57B | 2.73B | 2.54B | 2.72B | 3.29B | |||||
Other Operating Expenses, Total | 7.13B | 7.85B | 8.11B | 8.65B | 10.18B | |||||
Operating Income | 4.55B | 3.4B | 4.68B | 5.59B | 6.26B | |||||
Interest Expense, Total | -302M | -375M | -294M | -223M | -228M | |||||
Interest And Investment Income | 473M | 332M | 554M | 665M | 670M | |||||
Net Interest Expenses | 171M | -43.52M | 261M | 442M | 442M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | 1.27M | 1.02M | 1.24M | 22.35M | 20.9M | |||||
EBT, Excl. Unusual Items | 4.72B | 3.36B | 4.94B | 6.06B | 6.72B | |||||
Gain (Loss) On Sale Of Investments | 31.62M | 64.21M | 104M | 209M | 277M | |||||
Gain (Loss) On Sale Of Assets | -6M | 8.07M | -2.18M | -21.51M | -9.15M | |||||
Other Unusual Items | 4.95M | 6.96M | 9.29M | 3.35M | -298M | |||||
EBT, Incl. Unusual Items | 4.75B | 3.44B | 5.05B | 6.25B | 6.69B | |||||
Income Tax Expense | 1.25B | 1.03B | 1.43B | 1.33B | 1.59B | |||||
Earnings From Continuing Operations | 3.5B | 2.41B | 3.62B | 4.92B | 5.1B | |||||
Net Income to Company | 3.5B | 2.41B | 3.62B | 4.92B | 5.1B | |||||
Minority Interest | -54.58M | -22.29M | -45.58M | -51.14M | -49.75M | |||||
Net Income - (IS) | 3.45B | 2.39B | 3.58B | 4.87B | 5.05B | |||||
Net Income to Common Incl Extra Items | 3.45B | 2.39B | 3.58B | 4.87B | 5.05B | |||||
Net Income to Common Excl. Extra Items | 3.45B | 2.39B | 3.58B | 4.87B | 5.05B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 20.85 | 14.41 | 21.52 | 29.24 | 30.24 | |||||
Basic EPS - Continuing Operations | 20.85 | 14.41 | 21.52 | 29.24 | 30.24 | |||||
Basic Weighted Average Shares Outstanding | 165M | 166M | 166M | 167M | 167M | |||||
Net EPS - Diluted | 20.78 | 14.37 | 21.49 | 29.2 | 30.2 | |||||
Diluted EPS - Continuing Operations | 20.78 | 14.37 | 21.49 | 29.2 | 30.2 | |||||
Diluted Weighted Average Shares Outstanding | 166M | 166M | 166M | 167M | 167M | |||||
Normalized Basic EPS | 17.51 | 12.53 | 18.31 | 22.42 | 24.87 | |||||
Normalized Diluted EPS | 17.45 | 12.49 | 18.29 | 22.38 | 24.83 | |||||
Dividend Per Share | 6 | 6 | 12 | 12 | 14 | |||||
Payout Ratio | 33.83 | 43.13 | 55.76 | 41.03 | 42.99 | |||||
Supplemental Items | ||||||||||
EBITDA | 5.19B | 4.41B | 5.67B | 6.58B | 7.41B | |||||
EBITA | 4.78B | 3.93B | 5.21B | 6.12B | 6.84B | |||||
EBIT | 4.55B | 3.4B | 4.68B | 5.59B | 6.26B | |||||
EBITDAR | 5.45B | 4.66B | 5.94B | 6.89B | 7.73B | |||||
Total Revenues (As Reported) | 21.4B | 20.59B | 22.96B | 25.55B | 28.64B | |||||
Effective Tax Rate - (Ratio) | 26.25 | 29.88 | 28.32 | 21.21 | 23.81 | |||||
Total Current Taxes | 1.26B | 1.08B | 1.48B | 1.72B | 1.59B | |||||
Total Deferred Taxes | -17.88M | -51.41M | -48.67M | -395M | 520K | |||||
Normalized Net Income | 2.89B | 2.08B | 3.04B | 3.73B | 4.15B | |||||
Interest on Long-Term Debt | 199M | 223M | 200M | 192M | 227M | |||||
Non-Cash Pension Expense | 4.65M | 9.9M | 13.74M | 62.57M | 292M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 368M | 508M | 733M | 778M | 910M | |||||
Selling and Marketing Expenses | 368M | 508M | 733M | 778M | 910M | |||||
General and Administrative Expenses | 2.85B | 2.82B | 3.13B | 3.42B | 4.02B | |||||
Net Rental Expense, Total | 261M | 249M | 272M | 306M | 326M | |||||
Imputed Operating Lease Interest Expense | 184M | 157M | 192M | 270M | 333M | |||||
Imputed Operating Lease Depreciation | 76.41M | 91.94M | 80.19M | 35.93M | -7.65M | |||||
Maintenance & Repair Expenses, Total | 526M | 683M | 716M | 735M | 813M | |||||
Stock-Based Comp., COGS (Total) | 323M | 228M | 217M | 271M | 238M | |||||
Total Stock-Based Compensation | 323M | 228M | 217M | 271M | 238M |
- Stock Market
- Stocks
- LALPATHLAB Stock
- Financials Dr. Lal PathLabs Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















